Mar 21, 2017 - The withdrawal of Array Biopharma’s (NASDAQ:ARRY) filing for binimetinib is, on the face of it, not too big a deal. The company had sought approval in Nras-mutant melanoma, a much smaller indication t
May 10, 2017 - Shares in Array BioPharma Inc. were soaring in early Wednesday trading, even though the company announced a bigger loss and smaller third-quarter revenues compared with last year.
That's because the Boulder biotech announced "positive" results from a study of its drug targeting unresectable or metastatic melanoma.
The study results "represents a potential important addition to the ... treatment landscape for patients with BRAF-mutant melanoma," said Ron Squarer, CEO, in a statement.
Jul 06, 2017 - Biotech continues to meander in trading amid a dearth of new M&A activity.Biotech stalwart Celgene continues to make significant collaboration deals throughout the industry across myriad disease areas
May 11, 2017 - Roche takes a surprising left in immunotherapy.Array is charting new lands in the COLUMBUS study.Allergan completes enrollment in its wet AMD studies.
May 10, 2017 - Array Biopharma's financial results get the back seat today, while clinical-trial results ride shotgun.
Jun 09, 2017 -
Jim Cramer said on CNBC's "Mad Money" that Foot Locker, Inc. (NYSE: FL) didn't have a great quarter so he isn't recommending it as a buy at the moment.
Mar 22, 2017 - This is not an attack on the energy industry or its major players.It is a comparison of the views being held by the big-money clients of Market-Makers as to their investment alternatives.It also offer
Dec 19, 2017 -
Despite a 15-percent decline throughout 2017, ARRIS International plc (NASDAQ: ARRS) was still favorably viewed by some on the Street, but on Tuesday a notable analyst changed their previously bullish thesis.
Jul 16, 2018 - Array's melanoma combo gets a guideline nod. Atossa looks for a window of opportunity in breast cancer. Astellas and Pfizer score widened approval for Xtandi.
Oct 27, 2015 - SF-based MYOK is a clinical-stage biopharmaceutical, developing therapies for rare and serious cardiovascular diseases. MYOK scheduled a ~$74 million NASDAQ IPO; lead underwriters Cowen & Credit Suiss